Alport Syndrome

Gene therapy research for kidney disease funded

Published in Gene Therapy Weekly, October 24th, 2002

BioStratum Incorporated, which develops drugs based on basal lamina research, has signed an agreement granting Genzyme Corporation an option to obtain a worldwide license under BioStratum's patent rights pertaining to the diagnosis and treatment of Alport syndrome.

Alport syndrome is an inherited kidney disease that is highly progressive, often leading to kidney failure. It affects about 1 in 5000 Americans, striking men more often and severely than women. The defective gene responsible for the disease was first located in 1988, and today over 200 mutations have been identified, most in the gene that codes for the alpha-5 chain of type IV collagen. No specific...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-10-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry